Based in Emeryville, California, and founded in 1981, XOMA Corporation functions as a specialized biotechnology royalty aggregator, with operations spanning Europe, the United States, and the Asia Pacific. The company's core mission is to contribute to advancing human health by empowering other biotechnology firms. XOMA achieves this by purchasing the future economic interests, often in the form of royalties, associated with therapeutic candidates still in their pre-commercial development stages, which have already been licensed to pharmaceutical or biotechnology partners. Their strategic focus is primarily on early to mid-stage clinical assets, specifically those in Phase 1 and 2, that demonstrate significant potential for commercial sales once fully developed by their licensees. Currently, XOMA manages a substantial portfolio comprising approximately 70 such assets.